Biodesix Inc. (Nasdaq: BDSX), a Louisville-based diagnostic solutions company, saw its stock price dive in early trading Thursday after the company went public with its plans to initiate a one-for-20 reverse stock split next week.

The reverse split, which will be effective as of Monday, will reduce Biodesix’s outstanding common shares from about 156 million to roughly 8 million.

Such moves are often made to boost naggingly low stock prices and regain compliance with exchange minimums. This is likely to be the case with Biodesix’s reverse stock split.

The company received a delisting warning from Nasdaq in March, which gave Biodesix until Sept. 22 to raise its stock price above the $1 minimum listing threshold.

“The Company intends to monitor the closing bid price of its common stock an

See Full Page